|
summary: This analysis of a subgroup of patients from the PROMiSe trial (Trial of glatiramer acetate therapy in primary progressive MS) who underwent spectroscopy imaging showed that there was no differences in metabolite concentrations in the brains of patients who were treated with glatiramer acetate and those that were not. This suggests that treated patients did not derive any protection from the drug.
authors: Sajja BR, Narayana PA, Wolinsky JS, Ahn CW; the PROMiSe Trial MRSI Group.
source: Mult Scler. 2008 Jan;14(1):73-80. Epub 2007 Sep 19.
weblink: click here
category: Imaging
related research news: click here
glossary:
ACE
Brain
Glatiramer
Magnetic
Multiple sclerosis
Primary progressive MS
Sclerosis
|
